MCID: PST029
MIFTS: 36

Postmenopausal Atrophic Vaginitis

Categories: Reproductive diseases

Aliases & Classifications for Postmenopausal Atrophic Vaginitis

MalaCards integrated aliases for Postmenopausal Atrophic Vaginitis:

Name: Postmenopausal Atrophic Vaginitis 12 15 73
Atrophic Vaginitis 12 76
Senile Vaginitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11968
ICD10 33 N95.2
ICD9CM 35 627.3
SNOMED-CT 68 156054004 52441000
UMLS 73 C0156409

Summaries for Postmenopausal Atrophic Vaginitis

MalaCards based summary : Postmenopausal Atrophic Vaginitis, also known as atrophic vaginitis, is related to vaginitis and lipid-rich carcinoma. An important gene associated with Postmenopausal Atrophic Vaginitis is PRLR (Prolactin Receptor), and among its related pathways/superpathways are Prolactin Signaling Pathway and TGF-beta Signaling Pathways. The drugs Hyaluronic acid and Apricot have been mentioned in the context of this disorder. Related phenotypes are behavior/neurological and adipose tissue

Wikipedia : 76 Atrophic vaginitis is the chronic and progressive inflammation of the vagina (and the lower urinary... more...

Related Diseases for Postmenopausal Atrophic Vaginitis

Diseases related to Postmenopausal Atrophic Vaginitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Related Disease Score Top Affiliating Genes
1 vaginitis 29.2 AR ESR1 ESR2
2 lipid-rich carcinoma 10.4 ESR1 PRLR
3 progesterone resistance 10.3 ESR1 ESR2
4 progesterone-receptor positive breast cancer 10.3 ESR1 ESR2
5 sexual disorder 10.3 OXT SHBG
6 47, xxy 10.3 AR SHBG
7 androgen insensitivity, partial 10.3 AR SHBG
8 hyperprolactinemia 10.3 PRLR SHBG
9 prostatic adenoma 10.3 AR SHBG
10 breast abscess 10.3 FLNA OXT
11 premenstrual tension 10.2 OXT SHBG
12 dental fluorosis 10.2 ESR1 ESR2
13 endometriosis of ovary 10.2 ESR1 ESR2
14 alopecia, androgenetic, 1 10.2 AR SHBG
15 endometrial disease 10.2 ESR1 OXT
16 androgenic alopecia 10.2 AR SHBG
17 complete androgen insensitivity syndrome 10.2 AR SHBG
18 lower urinary tract calculus 10.2 AR FLNA
19 endometritis 10.2 ESR1 OXT
20 sex differentiation disease 10.2 AR SHBG
21 oncocytic breast carcinoma 10.2 AR ESR1
22 endometrial squamous cell carcinoma 10.2 AR ESR1
23 apocrine adenocarcinoma 10.1 AR ESR1
24 pelvic organ prolapse 10.1 ESR1 ESR2
25 breast adenoid cystic carcinoma 10.1 AR ESR1
26 androgen insensitivity syndrome 10.1 AR SHBG
27 uterine anomalies 10.1 ESR1 OXT
28 transsexualism 10.1 AR ESR2
29 bone resorption disease 10.0 ESR1 ESR2
30 prostatic hypertrophy 10.0 AR ESR1
31 testicular germ cell cancer 10.0 AR ESR2
32 gonadal disease 10.0 AR SHBG
33 sweat gland cancer 10.0 AR ESR1
34 idiopathic scoliosis 10.0 ESR1 ESR2
35 estrogen-receptor negative breast cancer 10.0 AR ESR1
36 female breast cancer 9.9 AR ESR1
37 endometrial adenocarcinoma 9.9 ESR1 ESR2
38 lobular neoplasia 9.9 ESR1 ESR2 PRLR
39 estrogen excess 9.9 ESR1 ESR2 SHBG
40 myoma 9.9 ESR1 OXT
41 sporadic breast cancer 9.8 ESR1 ESR2
42 gynecomastia 9.7 AR ESR1 SHBG
43 male reproductive organ cancer 9.7 AR ESR2 SHBG
44 gender identity disorder 9.6 AR ESR1 ESR2
45 ductal carcinoma in situ 9.5 AR ESR1
46 breast disease 9.5 ESR1 ESR2 PRLR SHBG
47 endocrine gland cancer 9.3 AR ESR1
48 female reproductive system disease 9.3 ESR1 ESR2 OXT SHBG
49 osteoporosis 9.1 AR ESR1 ESR2 SHBG
50 endometrial cancer 9.1 AR ESR1 ESR2 SHBG

Comorbidity relations with Postmenopausal Atrophic Vaginitis via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety
Deficiency Anemia Female Stress Incontinence
Hypertension, Essential Hypothyroidism
Osteoporosis

Graphical network of the top 20 diseases related to Postmenopausal Atrophic Vaginitis:



Diseases related to Postmenopausal Atrophic Vaginitis

Symptoms & Phenotypes for Postmenopausal Atrophic Vaginitis

MGI Mouse Phenotypes related to Postmenopausal Atrophic Vaginitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.93 FLNA AR OXT ESR1 PRLR ESR2
2 adipose tissue MP:0005375 9.88 AR OXT ESR1 PRLR ESR2
3 digestive/alimentary MP:0005381 9.83 AR FLNA OXT ESR1 ESR2
4 endocrine/exocrine gland MP:0005379 9.8 ESR2 AR OXT ESR1 PRLR
5 integument MP:0010771 9.77 AR OXT ESR1 PRLR ESR2
6 nervous system MP:0003631 9.63 FLNA AR OXT ESR1 PRLR ESR2
7 limbs/digits/tail MP:0005371 9.62 ESR2 AR ESR1 PRLR
8 neoplasm MP:0002006 9.56 AR ESR1 PRLR ESR2
9 reproductive system MP:0005389 9.43 AR FLNA OXT ESR1 PRLR ESR2
10 skeleton MP:0005390 9.02 ESR2 FLNA AR ESR1 PRLR

Drugs & Therapeutics for Postmenopausal Atrophic Vaginitis

Drugs for Postmenopausal Atrophic Vaginitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 59)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
2 Apricot Approved, Nutraceutical Phase 4
3 Adjuvants, Immunologic Phase 4,Phase 3
4 Protective Agents Phase 4
5 Viscosupplements Phase 4
6 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Estrogens, Conjugated (USP) Phase 4,Phase 3,Phase 1,Not Applicable
8 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757
12 Estradiol valerate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 979-32-8
13
Polyestradiol phosphate Approved Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
14
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
15
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
16 Contraceptive Agents Phase 3,Phase 2,Phase 1,Not Applicable
17 Estradiol 17 beta-cypionate Phase 3,Phase 2,Phase 1,Not Applicable
18 Estradiol 3-benzoate Phase 3,Phase 2,Phase 1,Not Applicable
19 Antineoplastic Agents, Hormonal Phase 3,Phase 1,Phase 2
20 Appetite Stimulants Phase 3
21 Central Nervous System Stimulants Phase 3
22 Contraceptives, Oral Phase 3
23
Megestrol Phase 3 3562-63-8 19090 3080587
24 Pycnogenols Nutraceutical Phase 3
25 DHEA (Dehydroepiandrosterone) Nutraceutical Phase 3
26
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
27
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
28
Loperamide Approved Phase 2 53179-11-6 3955
29
Methyltestosterone Approved Phase 1, Phase 2 58-18-4 6010
30
Testosterone Approved, Investigational Phase 1, Phase 2 58-22-0 6013
31
Testosterone enanthate Approved Phase 1, Phase 2 315-37-7 9416
32
Testosterone undecanoate Approved, Investigational Phase 1, Phase 2 5949-44-0
33
Caffeine Approved, Nutraceutical Phase 2 58-08-2 2519
34 Oxytocics Phase 2
35 Aromatase Inhibitors Phase 2,Phase 1,Not Applicable
36 Progestins Phase 2
37 Antidiarrheals Phase 2
38 Calcium polycarbophil Phase 2
39 Calcium, Dietary Phase 2
40 Cathartics Phase 2
41 Estrogen Antagonists Phase 2,Phase 1,Not Applicable
42 Gastrointestinal Agents Phase 2
43 Laxatives Phase 2
44 Steroid Synthesis Inhibitors Phase 2,Phase 1,Not Applicable
45 Anabolic Agents Phase 1, Phase 2
46 Androgens Phase 1, Phase 2
47 Emollients Phase 1, Phase 2
48 Testosterone 17 beta-cypionate Phase 1, Phase 2
49 Omega 3 Fatty Acid Nutraceutical Phase 2
50 Echinacea Nutraceutical Phase 1, Phase 2

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Oral Low-molecular Weight Hyaluronic Acid in the Treatment of Atrophic Vaginitis Completed NCT02014428 Phase 4 Placebo
2 Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients Completed NCT03032848 Phase 4 Conjugated Estrogen;Promestriene;Estriol;Vaginal Moisturizer - Cream
3 Vaginal and Urinary Microbiome Trial Recruiting NCT02869165 Phase 4 Premarin vaginal cream;Apricot kernel oil
4 Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis Completed NCT03294538 Phase 3 Estrace® Cream;Generic Estradiol Cream;Vehicle Cream
5 Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis Completed NCT00137371 Phase 3 PVC (daily for 21 days, 7 days off);PVC (twice weekly)
6 Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms Completed NCT00108849 Phase 3 estradiol, 10 mcg
7 A Multi-Site Study Comparing Estradiol Vaginal Cream (0.01%) to Estrace® Cream (0.01%) in Postmenopausal Females With Atrophic Vaginitis Completed NCT02995694 Phase 3 Estradiol;Placebos;Reference
8 A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis Completed NCT02195986 Phase 3 Estradiol Vaginal Cream, 0.01%;Estrace® 0.01% cream;Placebo Vaginal Cream
9 Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial Completed NCT00464971 Phase 3 estradiol, 25 mcg
10 Efficacy and Safety of 17-Beta Estradiol in Treatment of Atrophic Vaginitis Completed NCT00465192 Phase 3 estradiol, 10 mcg;estradiol, 25 mcg;placebo
11 Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis Completed NCT00431132 Phase 3 estradiol, 10 mcg
12 Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo Completed NCT01779947 Phase 3 Estradiol Vaginal Tablets 10 mcg;placebo
13 S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast Cancer Completed NCT00005975 Phase 3 Megestrol Acetate 20mg/day;Megestrol Acetate 40 mg/day;Megestrol Acetate Placebo 20 mg/day;Megestrol Acetate Placebo 40 mg/day
14 Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause Completed NCT02013544 Phase 3 Placebo;Prasterone (DHEA)
15 Topical DHEA Against Vaginal Atrophy Completed NCT01846442 Phase 3 Placebo;DHEA (0.25%);DHEA (0.5%);DHEA (1.0%)
16 Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy Completed NCT01358760 Phase 3 Placebo;DHEA;DHEA
17 DHEA Against Vaginal Atrophy - 3-Month Efficacy Study Completed NCT01256684 Phase 3 Placebo;DHEA;DHEA
18 DHEA Against Vaginal Atrophy - Safety Study of 12 Months Completed NCT01256671 Phase 3 DHEA
19 The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse Completed NCT00803335 Phase 3 Vaginal conjugated estrogen cream 0.5gm;Vaginal conjugated estrogen cream 1.0gm
20 A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis Terminated NCT00816556 Phase 3 Estriol;Estradiol valerate;Vanicream Lite
21 Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors Unknown status NCT02150525 Phase 2
22 Phase I-B Study to Evaluate the Safety, Tolerability and Efficacy of IZN-6NVS for the Treatment of AV and DIV Completed NCT02313545 Phase 1, Phase 2 IZN-6NVS Cream
23 An Efficacy Study of Vagitocin in Postmenopausal Women With Symptoms of Vaginal Atrophy Completed NCT02497547 Phase 2 Oxytocin;Placebo
24 Microbiological Impact of an Intimate Cream and Its Suitability to Contribute to the Feeling of Softness and Freshness in the Intimate Area of Women Completed NCT02162160 Phase 2 Placebo
25 Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy Recruiting NCT02460302 Phase 2 Vaginal progesterone;Placebo
26 REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy Recruiting NCT01984138 Phase 2 ESTRING;Replens
27 Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer. Suspended NCT01122342 Phase 1, Phase 2 Testosterone propionate
28 The Treatment Effect of Chinese Herbal Compound Ointment on Atrophic Vaginitis Unknown status NCT02733731 Phase 1 Chinese Herbal Compound Ointment;Estriol
29 Study Comparing Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Atrophic Vaginitis Completed NCT00167921 Phase 1 Premarin® Vaginal Cream;Premarin® oral tablets
30 Clinical Study of Vaginal Lactobacilli and Estriol (Gynoflor®) for Atrophic Vaginitis in Breast Cancer Patients Completed NCT01370551 Phase 1 Gynoflor
31 Pharmacokinetic Assessment of the Absorption of Estradiol in Postmenopausal Women With Atrophic Vaginitis Completed NCT01486979 Phase 1 estradiol, 10 mcg;estradiol, 25 mcg
32 Comparison of Two Vaginal Tablets, Produced at Different Sites, in Postmenopausal Women With Atrophic Vaginitis Completed NCT01085877 Phase 1 estradiol, 25 mcg;estradiol, 25 mcg
33 Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency Completed NCT01507454 estradiol, 25 mcg
34 Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness Completed NCT02029053 Early Phase 1
35 A Review on the Outcome of Patient Managed in Postmenopausal Bleeding Clinic Recruiting NCT03382145
36 Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen Active, not recruiting NCT00984399 Not Applicable Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
37 Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy Suspended NCT02691936 Not Applicable Estrogens, Conjugated (USP)

Search NIH Clinical Center for Postmenopausal Atrophic Vaginitis

Genetic Tests for Postmenopausal Atrophic Vaginitis

Anatomical Context for Postmenopausal Atrophic Vaginitis

Publications for Postmenopausal Atrophic Vaginitis

Articles related to Postmenopausal Atrophic Vaginitis:

# Title Authors Year
1
Local estrogen replacement therapy in postmenopausal atrophic vaginitis: efficacy and safety of low dose 17beta-estradiol vaginal tablets. ( 16108394 )
2005

Variations for Postmenopausal Atrophic Vaginitis

Expression for Postmenopausal Atrophic Vaginitis

Search GEO for disease gene expression data for Postmenopausal Atrophic Vaginitis.

Pathways for Postmenopausal Atrophic Vaginitis

GO Terms for Postmenopausal Atrophic Vaginitis

Biological processes related to Postmenopausal Atrophic Vaginitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription initiation from RNA polymerase II promoter GO:0006367 9.43 AR ESR1 ESR2
2 negative regulation of DNA binding transcription factor activity GO:0043433 9.4 ESR1 FLNA
3 intracellular receptor signaling pathway GO:0030522 9.37 AR ESR1
4 intracellular estrogen receptor signaling pathway GO:0030520 9.32 ESR1 ESR2
5 mammary gland alveolus development GO:0060749 9.16 AR ESR1
6 cytoplasmic sequestering of protein GO:0051220 8.96 FLNA GET4
7 steroid hormone mediated signaling pathway GO:0043401 8.8 AR ESR1 ESR2

Molecular functions related to Postmenopausal Atrophic Vaginitis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 lipid binding GO:0008289 9.73 AR ESR1 ESR2 SHBG
2 enzyme binding GO:0019899 9.67 AR ESR1 ESR2
3 transcription factor binding GO:0008134 9.65 AR ESR1 FLNA
4 core promoter sequence-specific DNA binding GO:0001046 9.46 ESR1 ESR2
5 steroid hormone receptor activity GO:0003707 9.43 AR ESR1 ESR2
6 estrogen receptor activity GO:0030284 9.4 ESR1 ESR2
7 androgen binding GO:0005497 9.37 AR SHBG
8 nuclear receptor activity GO:0004879 9.33 AR ESR1 ESR2
9 estrogen response element binding GO:0034056 9.32 ESR1 ESR2
10 RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding GO:0038052 8.96 ESR1 ESR2
11 steroid binding GO:0005496 8.92 AR ESR1 ESR2 SHBG

Sources for Postmenopausal Atrophic Vaginitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....